English
Belinostat (PXD101) , CAS 414864-00-9
Belinostat (PXD101) , CAS 414864-00-9
Artikelnummer
BPS27608-3
Verpackungseinheit
100 mg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Background: Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines.
Biological Activity: Belinostat (also known as PXD101) is a novel and potent hydroxamate-type inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC in Hela cell extracts with IC50 value of 27 nM. In the treatment of urothelial carcinoma cell lines, belinostat dose-dependently inhibits proliferation in 5637, T24, J82 and RT4 cells with IC50 values of 1.0 µM, 3.5 µM, 6.0 µM and 10 µM respectively; while, in prostate cancer cell lines, it inhibits cancer cell growth with IC50 values ranging from 0.5 to 2.5 µM.
CAS Number: 414864-00-9
Description: Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.
Purity: ≥98% by HPLC
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: 1. Buckley,MT, et al. J. Transl. Med. 2007; 5:49.
2. Gravina, GL et al. Int. J. Oncol. 40: 711-720, 2012.
3. Plumb JA, et al. Mol Cancer Ther. 2003 Aug;2(8):721-8.
Background: Belinostat has been found to significantly increase the acetylation of histones H3 and H4 and exerts cytotoxicity in a wide range of tumor cell lines.
Biological Activity: Belinostat (also known as PXD101) is a novel and potent hydroxamate-type inhibitor of histone deacetylase (HDAC) that inhibits the activity of HDAC in Hela cell extracts with IC50 value of 27 nM. In the treatment of urothelial carcinoma cell lines, belinostat dose-dependently inhibits proliferation in 5637, T24, J82 and RT4 cells with IC50 values of 1.0 µM, 3.5 µM, 6.0 µM and 10 µM respectively; while, in prostate cancer cell lines, it inhibits cancer cell growth with IC50 values ranging from 0.5 to 2.5 µM.
CAS Number: 414864-00-9
Description: Belinostat, also known as PXD101, is a novel and potent hydroxamate-type HDAC inhibitor.
Purity: ≥98% by HPLC
Solubility: Soluble in DMSO
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: HDAC
Biosafety Level: Not applicable (BSL-1)
References: 1. Buckley,MT, et al. J. Transl. Med. 2007; 5:49.
2. Gravina, GL et al. Int. J. Oncol. 40: 711-720, 2012.
3. Plumb JA, et al. Mol Cancer Ther. 2003 Aug;2(8):721-8.
| Artikelnummer | BPS27608-3 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 27608-3 |
| Green Labware | Nein |
| Verpackungseinheit | 100 mg |
| Mengeneinheit | STK |
| Produktinformation (PDF) |
|
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
